209 related articles for article (PubMed ID: 26824047)
21. Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study.
Ueno M; Ferreiro JL; Desai B; Tomasello SD; Tello-Montoliu A; Capodanno D; Capranzano P; Kodali M; Dharmashankar K; Charlton RK; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2012 Mar; 5(3):293-300. PubMed ID: 22440495
[TBL] [Abstract][Full Text] [Related]
22. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F
Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056
[TBL] [Abstract][Full Text] [Related]
23. A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients.
Straub N; Beivers A; Lenk E; Aradi D; Sibbing D
Thromb Haemost; 2014 Feb; 111(2):290-9. PubMed ID: 24154566
[TBL] [Abstract][Full Text] [Related]
24. Platelet function testing to predict hyporesponsiveness to clopidogrel in patients with chest pain seen in the emergency department.
Sharma RK; Erickson SW; Sharma R; Voelker DJ; Reddy HK; Dod H; Marsh JD
Vasc Health Risk Manag; 2013; 9():187-93. PubMed ID: 23662064
[TBL] [Abstract][Full Text] [Related]
25. Switching between P2Y
Capranzano P; Capodanno D
Vascul Pharmacol; 2019 May; 116():4-7. PubMed ID: 30876967
[TBL] [Abstract][Full Text] [Related]
26. High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study.
Chirumamilla AP; Maehara A; Mintz GS; Mehran R; Kanwal S; Weisz G; Hassanin A; Hakim D; Guo N; Baber U; Pyo R; Moses JW; Fahy M; Kovacic JC; Dangas GD
JACC Cardiovasc Imaging; 2012 May; 5(5):540-9. PubMed ID: 22595163
[TBL] [Abstract][Full Text] [Related]
27. Translation of experimental cardioprotective capability of P2Y
Hjortbak MV; Olesen KKW; Seefeldt JM; Lassen TR; Jensen RV; Perkins A; Dodd M; Clayton T; Yellon D; Hausenloy DJ; Bøtker HE;
Basic Res Cardiol; 2021 May; 116(1):36. PubMed ID: 34037861
[TBL] [Abstract][Full Text] [Related]
28. Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?
Laine M; Camoin-Jau L; Bessereau J; Sébastien A; Paganelli F; Bonello L
Curr Pharm Des; 2012; 18(33):5392-401. PubMed ID: 22724420
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model.
Ravnefjord A; Weilitz J; Emanuelsson BM; van Giezen JJ
Thromb Res; 2012 Oct; 130(4):622-8. PubMed ID: 22909827
[TBL] [Abstract][Full Text] [Related]
30. Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Aradi D; Komócsi A; Vorobcsuk A; Serebruany VL
Thromb Haemost; 2013 Jan; 109(1):93-101. PubMed ID: 23197191
[TBL] [Abstract][Full Text] [Related]
31. Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study.
Bernlochner I; Mayer K; Orban M; Morath T; Jaitner J; Rössner L; Gross L; Laugwitz KL; Kastrati A; Sibbing D
Platelets; 2016 Dec; 27(8):796-804. PubMed ID: 27275651
[TBL] [Abstract][Full Text] [Related]
32. Impact of Reticulated Platelets on the Antiplatelet Effect of the Intravenous P2Y12-Receptor Inhibitor Cangrelor.
Stratz C; Nührenberg T; Valina CM; Löffelhardt N; Mashayekhi K; Ferenc M; Trenk D; Neumann FJ; Hochholzer W
Thromb Haemost; 2018 Feb; 118(2):362-368. PubMed ID: 29443372
[TBL] [Abstract][Full Text] [Related]
33. High platelet reactivity on aspirin in patients with acute ST elevation myocardial infarction.
Dillinger JG; Saeed A; Spagnoli V; Sollier CB; Sideris G; Silberman SM; Voicu S; Drouet L; Henry P
Thromb Res; 2016 Aug; 144():56-61. PubMed ID: 27289074
[TBL] [Abstract][Full Text] [Related]
34. New antiplatelet agents in the treatment of acute coronary syndromes.
Sabouret P; Taiel-Sartral M
Arch Cardiovasc Dis; 2014 Mar; 107(3):178-87. PubMed ID: 24630752
[TBL] [Abstract][Full Text] [Related]
35. Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Thomas MR; Outteridge SN; Ajjan RA; Phoenix F; Sangha GK; Faulkner RE; Ecob R; Judge HM; Khan H; West LE; Dockrell DH; Sabroe I; Storey RF
Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2562-70. PubMed ID: 26515417
[TBL] [Abstract][Full Text] [Related]
36. Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome.
Bonello L; Laine M; Camoin-Jau L; Noirot F; Guieu R; Dignat-George F; Paganelli F; Frere C
Thromb Haemost; 2015 Oct; 114(4):702-7. PubMed ID: 26311415
[TBL] [Abstract][Full Text] [Related]
37. Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials.
Zhou Y; Wang Y; Wu Y; Huang C; Yan H; Zhu W; Xu W; Zhang L; Zhu J
BMC Cardiovasc Disord; 2017 Jun; 17(1):157. PubMed ID: 28619104
[TBL] [Abstract][Full Text] [Related]
38. [Myocardial infarction: Role of new antiplatelet agents].
Silvain J; Bellemain A; Ecollan P; Montalescot G; Collet JP
Presse Med; 2011 Jun; 40(6):615-24. PubMed ID: 21511430
[TBL] [Abstract][Full Text] [Related]
39. The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study.
Samoš M; Fedor M; Kovář F; Galajda P; Bolek T; Stančiaková L; Fedorová J; Staško J; Kubisz P; Mokáň M
J Diabetes Res; 2016; 2016():2909436. PubMed ID: 27493970
[TBL] [Abstract][Full Text] [Related]
40. ADP-receptor inhibitors in the perioperative period: the good, the bad, and the ugly.
Oprea AD; Popescu WM
J Cardiothorac Vasc Anesth; 2013 Aug; 27(4):779-95. PubMed ID: 23648080
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
